AUPH

AI Memo

Aurinia

As of 2026-10-25/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-25 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

2026 LUPKYNIS sales versus guidance • 2026-12-31

Base target: $19 / p=50% prob

Biggest risk

Aurinia reiterated rather than raised 2026 guidance. Zacks reported adjusted EPS of $0.28 versus its $0.19 consensus estimate, but revenue was approximately in line; its pre-release estimate-revision trend was unfavorable. Post-print analyst target and estimate revisions were not supplied. Other generic patent cases remain pending, while development spending and competitive treatments create execution risk. Zacks report SEC exhibit

Invalidation

Break below $13 or thesis failure.

What would change my mind?

Q2 revenue increased 19% year over year to $83.2 million, net income reached $37.4 million, and operating cash flow was $52.5 million. LUPKYNIS growth, $443.1 million of cash and investments at June 30, and the Teva settlement support the positive directional prior. [#SEC-8K-2026-08-06] [#8-K-2026-08-19]

Research note

Recommendation

—

Confidence

medium

As of

2026-10-25

Base target

$19

p=50%

Bull target

$22

p=30%

Bear target

$13

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Reassessment of Teva patent settlement
PRESERVE combination-study progress
Aritinercept program-specific development

BearKey bullets

Full-year LUPKYNIS sales could miss the reiterated $305 million–$315 million guidance range.
[#SEC-8K-2026-08-06]
PRESERVE and aritinercept lack supplied dated efficacy readouts; development progress should not be treated as proven clinical benefit.

WatchKey bullets

2026 LUPKYNIS sales versus guidance

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $19 (p=50%)

Target spread vs base: +19% / -32%

Scenario probabilities

Bull Target: $22 (p=30%)Base Target: $19 (p=50%)Bear Target: $13 (p=20%)

Commentary

The primary-source operating results and Teva settlement support a cautiously positive view, consistent with the packet's positive directional prior and strong evidence-quality score. Recent headline coverage is thin; a reliable post-release price reaction and post-print analyst revisions were not supplied. Zero-valued sentiment fields indicate unavailable measurements, not measured neutral readings.

As of 2026-10-25 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Reassessment of Teva patent settlement
PRESERVE combination-study progress
Aritinercept program-specific development

Scenarios

Bull Target (Scenario probability)

$22 / p=30% prob

Base Target (Scenario probability)

$19 / p=50% prob

Bear Target (Scenario probability)

$13 / p=20% prob

Analysis 2026-10-25 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
2026 LUPKYNIS sales versus guidance
Q2 LUPKYNIS net product sales rose 19% year over year to $79.4 million. Aurinia reiterated 2026 net product sales guidance of $305 million–$315 million; full-year delivery is the clearest near-term commercial test. [#SEC-8K-2026-08-06]
Prob 65.00% • Move 10.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Reassessment of Teva patent settlement
2026-12-31
Aurinia's Teva settlement provides for generic voclosporin launch no earlier than December 7, 2036, subject to earlier contingencies and FDA approval. Other generic patent actions remain pending, limiting how broadly the settlement can be applied. This is an already-announced development, not a new settlement forecast. [#8-K-2026-08-19] SEC exhibit
Prob 55% • Move 5% • Priced-in 80%

Long-term Catalysts

Months to a year

PRESERVE combination-study progress
2027-12-31
The Phase 4 PRESERVE study is investigating LUPKYNIS with selected biologics in lupus nephritis, with approximately 150 planned participants and complete renal response at six months as its primary endpoint. Enrollment and eventual data may inform combination use; no readout date was supplied. The date shown is a monitoring horizon, not company guidance. [#SEC-10Q-2026-08-06] SEC filing
Prob 45% • Move 8% • Priced-in 20%
Aritinercept program-specific development
2027-12-31
Aurinia reported that clinical development of aritinercept had begun in four potential autoimmune indications. Program-specific enrollment or efficacy evidence could broaden the thesis, but the reviewed material supplies no dated readout. The date shown is a monitoring horizon. [#SEC-10Q-2026-08-06] SEC filing
Prob 40% • Move 9% • Priced-in 25%

Risks

Full-year LUPKYNIS sales could miss the reiterated $305 million–$315 million guidance range. [#SEC-8K-2026-08-06]
PRESERVE and aritinercept lack supplied dated efficacy readouts; development progress should not be treated as proven clinical benefit.
Q2 research and development expense rose to $13.1 million from $7.4 million a year earlier, increasing the burden on future commercial cash generation. [#SEC-10Q-2026-08-06] SEC filing
The Teva agreement does not resolve patent actions against other generic applicants; its launch restriction also has defined earlier-entry contingencies. [#8-K-2026-08-19]

Peers

Symbol	Summary
PGEN	Similar packet market capitalization, but different products and clinical-stage economics make it only a loose size comparator, not a direct LUPKYNIS peer.
GSK	Benlysta treats active lupus nephritis, making GSK a direct indication competitor, but its diversified scale makes it a poor whole-company valuation multiple for Aurinia. GSK release

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-25

Loading AI feed…

Symbol

Summary

PGEN

Similar packet market capitalization, but different products and clinical-stage economics make it only a loose size comparator, not a direct LUPKYNIS peer.

GSK

Benlysta treats active lupus nephritis, making GSK a direct indication competitor, but its diversified scale makes it a poor whole-company valuation multiple for Aurinia. GSK release